Home » Newsletters » BioWorld Science

BioWorld Science

May 23, 2006

View Archived Issues

Active first quarter at Novo Nordisk

YM-529 inhibits bladder cancer cell growth

Safety and activity of CG-0070 in recurrent bladder cancer reported

Avanafil effective in men with mild to moderate erectile dysfunction

Study supports once-daily dosing of SLx-2101

Pretrial dosing begins with Conor Medsystems' dual-drug coronary stent

Jerini and Baxter report update on nonintravenous hemophilia therapy program

Novavax and Esprit to codevelop drug for female sexual desire disorder

Zenyth receives fourth milestone payment from Merck under asthma collaboration

Colorectal cancer patients included in phase I/II study of AP-12009

Phase IIa Atrigel/octreotide program in acromegaly delayed

Bavarian Nordic updates smallpox vaccine program

Phase II study begins for MK-0354 in patients with dyslipidemia

Phase II Oxycyte study in traumatic brain injury reaches treatment half-way post

CardioVascular BioTherapeutics achieves safety milestone in phase I heart trial

SRI awarded NIAID contract to produce oral formulations for antiradiation drugs

ConjuChem completes financing

Genzyme testing gene therapy for intermittent claudication

Fast track designation for Nektar's amphotericin B inhalation powder

Studies examine prolonged activity of once-daily tenatoprazole

Alvimopan improves gastrointestinal recovery after small bowel resection

Preclinical studies detail activity of asenapine

Recent patents cover novel analgesic agents

Novel agents for treating neurological disorders disclosed in recent patent literature

Recent patents describe new treatment options for endocrine-related disorders

The alpha7 nicotinic agonist AR-R17779 shows efficacy in a rat model of postoperative ileus

Intestinal inflammation may be reduced with cannabinoid receptor 2 agonists

Inhibition of heat shock protein 90 by KU-36 reduces prostate cancer proliferation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...